AR069847A1 - Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas - Google Patents
Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivasInfo
- Publication number
- AR069847A1 AR069847A1 ARP080105568A ARP080105568A AR069847A1 AR 069847 A1 AR069847 A1 AR 069847A1 AR P080105568 A ARP080105568 A AR P080105568A AR P080105568 A ARP080105568 A AR P080105568A AR 069847 A1 AR069847 A1 AR 069847A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- active ingredient
- digestive enzymes
- proteinal
- protected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente se refiere a composiciones farmacéuticas que comprenden, por lo menos, un ingrediente activo proteínico protegido contra las enzimas digestivas. Dichas composiciones farmacéuticas contienen dicho, por lo menos, un ingrediente activo proteínico, en forma libre, tal como, para líquidos, un sistema capaz de regularlos a un pH superior a 4 e inferior o igual a 8 o, para solidos, un sistema que ejerce, cuando se colocan en un medio líquido, un efecto buffer que oscila entre un pH superior a 4 y un pH inferior o igual a 8. Reivindicacion 5: Composicion de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque dicho por lo menos un ingrediente activo proteínico se selecciona entre: la insulina y sus análogos y derivados, la somatotropina y sus derivados, la calcitonina, y los análogos de LHRH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0759971A FR2925333B1 (fr) | 2007-12-19 | 2007-12-19 | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069847A1 true AR069847A1 (es) | 2010-02-24 |
Family
ID=39671377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105568A AR069847A1 (es) | 2007-12-19 | 2008-12-19 | Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas |
Country Status (19)
Country | Link |
---|---|
US (1) | US8309123B2 (es) |
EP (1) | EP2234598A1 (es) |
JP (1) | JP5676272B2 (es) |
KR (2) | KR101592609B1 (es) |
CN (1) | CN101917967B (es) |
AP (1) | AP3573A (es) |
AR (1) | AR069847A1 (es) |
AU (1) | AU2008345474B2 (es) |
BR (1) | BRPI0821373B8 (es) |
CA (1) | CA2709899C (es) |
EA (1) | EA023107B1 (es) |
FR (1) | FR2925333B1 (es) |
HK (1) | HK1146386A1 (es) |
IL (1) | IL206364A (es) |
MA (1) | MA31927B1 (es) |
MX (1) | MX2010006927A (es) |
TN (1) | TN2010000290A1 (es) |
TW (1) | TWI461226B (es) |
WO (1) | WO2009083686A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120035103A1 (en) * | 2010-01-29 | 2012-02-09 | Pillion Dennis J | Method for administration of insulin and pharmaceutical composition thereof |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
EP3137060B2 (en) | 2014-05-01 | 2023-12-20 | Sun Pharmaceutical Industries Ltd | Extended release suspension compositions |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
WO2016016845A1 (en) | 2014-07-30 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Dual-chamber pack |
US20180104197A9 (en) | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
WO2016071756A1 (en) * | 2014-11-04 | 2016-05-12 | Innopharmax, Inc. | Oral administration of unstable or poorly-absorbed drugs |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
FR3120189A1 (fr) * | 2021-03-01 | 2022-09-02 | Farid Bennis | Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE36225B1 (en) * | 1971-01-28 | 1976-09-15 | Nat Res Dev | Improvements relating to insulin derivatives |
US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
EP0179904A1 (en) | 1984-05-09 | 1986-05-07 | Medaphore Inc. | Oral insulin and a method of making the same |
US4693433A (en) * | 1986-06-06 | 1987-09-15 | Merrill David Martin | Unwind stand for web rolls |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
EP0781142A4 (en) * | 1994-09-01 | 2003-04-09 | Allied Medical Res Associates | COMPOSITIONS AND METHOD FOR PROVIDING POLYPEPTIDES |
US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
WO1999016417A1 (en) * | 1997-10-01 | 1999-04-08 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
US6531648B1 (en) * | 1998-12-17 | 2003-03-11 | Syngenta Participations Ag | Grain processing method and transgenic plants useful therein |
SI1031347T1 (en) * | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
SE9904121D0 (sv) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobe biomolecular structure |
US6531112B2 (en) * | 2000-05-15 | 2003-03-11 | Delrx Pharmaceutical Corporation | Formulations for administering calcitonin and processes for preparing the same |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
CN1335182A (zh) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
GB0119859D0 (en) * | 2001-08-15 | 2001-10-10 | Qinetiq Ltd | Eye tracking system |
US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
EP1765406A4 (en) * | 2004-05-21 | 2012-11-28 | Mediplex Corp | ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS |
WO2006014673A2 (en) * | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
EP2248531A1 (en) * | 2004-08-03 | 2010-11-10 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
PL1883394T3 (pl) | 2005-05-23 | 2018-09-28 | Sdg, Inc. | Konstrukt lipidowy do dostarczania insuliny ssakowi |
WO2007032018A1 (en) * | 2005-09-15 | 2007-03-22 | Council Of Scientific And Industrial Research | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES |
US20070134332A1 (en) * | 2005-11-21 | 2007-06-14 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
WO2007121318A2 (en) * | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
-
2007
- 2007-12-19 FR FR0759971A patent/FR2925333B1/fr active Active
-
2008
- 2008-12-18 JP JP2010538869A patent/JP5676272B2/ja active Active
- 2008-12-18 KR KR1020107013390A patent/KR101592609B1/ko active IP Right Grant
- 2008-12-18 EA EA201070746A patent/EA023107B1/ru unknown
- 2008-12-18 CN CN200880125189XA patent/CN101917967B/zh active Active
- 2008-12-18 MX MX2010006927A patent/MX2010006927A/es active IP Right Grant
- 2008-12-18 AU AU2008345474A patent/AU2008345474B2/en active Active
- 2008-12-18 WO PCT/FR2008/052357 patent/WO2009083686A1/fr active Application Filing
- 2008-12-18 EP EP08867946A patent/EP2234598A1/fr active Pending
- 2008-12-18 CA CA2709899A patent/CA2709899C/fr active Active
- 2008-12-18 AP AP2010005298A patent/AP3573A/xx active
- 2008-12-18 BR BRPI0821373A patent/BRPI0821373B8/pt active IP Right Grant
- 2008-12-18 KR KR1020157032578A patent/KR20150132887A/ko not_active Application Discontinuation
- 2008-12-19 AR ARP080105568A patent/AR069847A1/es unknown
- 2008-12-19 US US12/339,310 patent/US8309123B2/en active Active
- 2008-12-19 TW TW097149879A patent/TWI461226B/zh not_active IP Right Cessation
-
2010
- 2010-06-14 IL IL206364A patent/IL206364A/en active IP Right Grant
- 2010-06-18 TN TN2010000290A patent/TN2010000290A1/fr unknown
- 2010-06-18 MA MA32934A patent/MA31927B1/fr unknown
-
2011
- 2011-01-19 HK HK11100516.2A patent/HK1146386A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0821373A2 (pt) | 2015-06-16 |
TW200940107A (en) | 2009-10-01 |
HK1146386A1 (en) | 2011-06-03 |
AU2008345474A1 (en) | 2009-07-09 |
AU2008345474B2 (en) | 2014-07-31 |
FR2925333B1 (fr) | 2012-04-13 |
CN101917967A (zh) | 2010-12-15 |
CA2709899A1 (fr) | 2009-07-09 |
EA023107B1 (ru) | 2016-04-29 |
KR20100095449A (ko) | 2010-08-30 |
JP5676272B2 (ja) | 2015-02-25 |
KR20150132887A (ko) | 2015-11-26 |
TWI461226B (zh) | 2014-11-21 |
WO2009083686A9 (fr) | 2009-10-15 |
MA31927B1 (fr) | 2010-12-01 |
CA2709899C (fr) | 2018-01-16 |
IL206364A (en) | 2016-12-29 |
US20090176691A1 (en) | 2009-07-09 |
FR2925333A1 (fr) | 2009-06-26 |
CN101917967B (zh) | 2013-05-22 |
EA201070746A1 (ru) | 2011-02-28 |
KR101592609B1 (ko) | 2016-02-05 |
JP2011506587A (ja) | 2011-03-03 |
IL206364A0 (en) | 2010-12-30 |
US8309123B2 (en) | 2012-11-13 |
AP3573A (en) | 2016-02-08 |
WO2009083686A1 (fr) | 2009-07-09 |
MX2010006927A (es) | 2010-12-06 |
TN2010000290A1 (fr) | 2011-11-11 |
BRPI0821373B1 (pt) | 2020-04-22 |
AP2010005298A0 (en) | 2010-06-30 |
EP2234598A1 (fr) | 2010-10-06 |
BRPI0821373B8 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069847A1 (es) | Composiciones farmaceuticas que contienen, por lo menos, un ingrediente activo proteinico protegido contra las enzimas digestivas | |
TR200801337T1 (tr) | Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar. | |
RS54769B1 (sr) | Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo | |
IN2015MU00865A (es) | ||
PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
PH12021551279A1 (en) | Modified amine lipids | |
PH12014502778B1 (en) | Antibody formulation | |
BR112013032396A2 (pt) | formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
PE20131200A1 (es) | Composiciones herbicidas solidas con un adyuvante integrado | |
NO20092998L (no) | Flytende formuleringer, som danner dermal film, for frigjoring av legemidler til huden | |
TR201902010T4 (tr) | Bir ajanın oral alımına yönelik taşıyıcı cihaz. | |
CL2008001839A1 (es) | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. | |
MX2009013810A (es) | Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos. | |
MX340993B (es) | Agentes de suministro de acido fenilalquilcarboxilico. | |
SG10201901106WA (en) | Novel lipids and compositions for the delivery of therapeutics | |
TW200733968A (en) | Stabilized lanthanum carbonate compositions | |
AR081724A1 (es) | Composicion herbicida que contiene los hidratos de saflufenacilo y glifosato o glufosinato | |
ATE471144T1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
IN2014MN01470A (es) | ||
AR108631A1 (es) | Formulación de neurotoxinas | |
EP4249060A3 (en) | Liquid pharmaceutical composition of adalimumab | |
BR112012007842A2 (pt) | um copolímero em bloco e composição de poliesteramida com terminação éster e usos dos mesmos | |
EA201390646A1 (ru) | Фармацевтические композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |